News from our Journals

BJCP editorial highlights TAB08's potentially triumphant return

25 March 2015

An editorial in April's edition of the British Journal of Clinical Pharmacology describing how the drug TAB08 is being tested for use in treating rheumatoid arthritis has been covered by Reuters. The drug received extensive news coverage in 2006 when it caused dramatic side-effects in a clinical trial nine years ago at Northwick Park.

Since then, Profess David Webb, President Elect of the British Pharmacological Society, has explained the value of volunteers in clinical trials and the impact of improved safety measures in the UK since the 2006 Northwick Park clinical trial.

BJCP research used in Australian report on homeopathy

13 March 2015

Studies published in BJCP have been used in a report, published by the Australian National Health and Medical Research Council, that concludes, there is no good quality evidence to support the claim that homeopathy is effective in treating any health conditions. The three BJCP studies referenced by the Australian report were:

BJP press release coverage: Spider venom reveals potential to relieve chronic pain

04 March 2015

The BJP press release, New analysis of spider venom reveals seven promising compounds with the potential to relieve chronic pain has been covered by:


Daily Mail

Yahoo news

BPS and ASPET support publication of negative findings

11 September 2013

Two leading pharmacology societies, the British Pharmacological Society (BPS) and the American Society for Pharmacology and Experimental Therapeutics (ASPET), have announced their support for the publication of negative findings from early clinical trials. Their jointly published journal, Pharmacology Research & Perspectives, is at the same time launching an efficient and timely means for researchers to publish negative findings in two important areas: preclinical papers that show a hypothesis to be incorrect, and papers on drugs that have failed in early clinical development that can inform whether further drug development in warranted.

New Impact Factors for BPS journals

21 June 2013

The British Pharmacological Society (BPS) proudly announces the new Impact Factor results for its journals:

  • British Journal of Clinical Pharmacology achieved a result of 3.578, its highest ever Impact Factor (up from 2.958 last year)
  • British Journal of Pharmacology achieved a result of 5.067, regaining its position as the leading general research pharmacology journal (up from 4.409 last year)

Publishers aim to improve trial reporting

02 May 2013

BPS President-elect, Humphrey Rang contributed to the following Research Fortnight article on the role of publishers in clinical trials transparency.

Publishers of clinical trial results are examining the way they work to try to tackle publication bias and poor access to data.

Following criticisms made by the Wellcome Trust to the House of Commons Science and Technology Committee’s clinical trials inquiry last week, BioMed Central has told Research Fortnight that it is working to improve the International Standard Randomised Controlled Trial Number Register that it administers.

Official launch of journal Pharmacology Research & Perspectives at ASPET-BPS joint meeting

19 April 2013

Boston, MA — April 20, 2013—The American Society for Pharmacology and Experimental Therapeutics (ASPET), British Pharmacological Society (BPS) and John Wiley & Sons have issued a call for papers for their new open access, peer-reviewed journal, Pharmacology Research & Perspectives. The announcement was made as the three partners prepare for the official launch of the journal at the Joint ASPET-BPS Annual Meeting, taking place beginning April 20 as part of the Experimental Biology 2013 conference.

Search the News

Top Navigation

Search Area

Search the Site
Advanced Search

Members' Login Area

Members' Login U: P:

Need Help?